| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
Review |
Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens
The Methodist Hospital, Baylor College of Medicine, Scott Department of Urology, Section of Genitourinary Oncology, Houston, TX, USA
* Correspondence to: Dr R. J. Amato, D.O. 6560 Fannin Street, Suite 2100, Houston, TX 77030, USA. Tel: +1-713-798-8720; Fax: +1-713-798-5553; Email: ramato{at}bcm.tmc.edu
A search of the Medline database and ASCO 2003 conference proceedings was conducted to identify clinical trials currently underway using single-agent therapy for renal cell carcinoma (RCC). Combination trials were identified using the ASCO 2003 conference proceedings. Fourteen single-agent therapies employing different mechanisms of action were identified in the published literature: imatinib mesylate (Gleevec®); bevacizumab (Avastin®); thalidomide (Thalomid®); gefitinib (ZD1839) (Iressa®); cetuximab (IMC-C225) (ErbituxTM); bortezomib (PS-341) (Velcade®); HSPPC-96 (Oncophage®); BAY 59–8862; ABT-510; G250; CCI-779; SU5416; PTK/ZK; and ABX-EGF. Six distinct fields of clinical research have emerged: monoclonal antibodies, small molecules, vaccines, second-generation taxanes, nonapeptides and immunomodulators. Five combination regimens, primarily biological response modifiers (interleukin-2 or interferon-
), chemotherapy- or thalidomide-based, were identified. All therapies demonstrated acceptable toxicity profiles. Clinical benefit was assessed based on each study's reported criteria: antitumor response (regression or stability) ranged from 5% to 71%. In the past several years, significant advances in the underlying biological mechanisms of RCC, particularly the role of tumor angiogenesis, have permitted the design of molecularly targeted therapeutics. Based on preliminary and limited studies, combination therapies offer the greatest clinical benefit in the management of this malignancy, although additional basic research is still warranted.
Key words: bevacizumab, imatinib mesylate, renal cell carcinoma, thalidomide
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Y. Lee, D.-K. Kim, J. H. Cho, J.-Y. Koh, and Y. H. Yoon Inhibitory Effect of Bevacizumab on the Angiogenesis and Growth of Retinoblastoma Arch Ophthalmol, July 1, 2008; 126(7): 953 - 958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kusmartsev, E. Eruslanov, H. Kubler, T. Tseng, Y. Sakai, Z. Su, S. Kaliberov, A. Heiser, C. Rosser, P. Dahm, et al. Oxidative Stress Regulates Expression of VEGFR1 in Myeloid Cells: Link to Tumor-Induced Immune Suppression in Renal Cell Carcinoma J. Immunol., July 1, 2008; 181(1): 346 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Faria, C. S. Ng, K. R. Hess, S. Phongkitkarun, J. Szejnfeld, D. Daliani, and C. Charnsangavej CT Quantification of Effects of Thalidomide in Patients with Metastatic Renal Cell Carcinoma Am. J. Roentgenol., August 1, 2007; 189(2): 378 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ito, M. Eto, E. Nakamura, A. Takahashi, T. Tsukamoto, H. Toma, H. Nakazawa, Y. Hirao, H. Uemura, S. Kagawa, et al. STAT3 Polymorphism Predicts Interferon-Alfa Response in Patients With Metastatic Renal Cell Carcinoma J. Clin. Oncol., July 1, 2007; 25(19): 2785 - 2791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Jones and T. A. Libermann Genomics of Renal Cell Cancer: The Biology Behind and the Therapy Ahead Clin. Cancer Res., January 15, 2007; 13(2): 685s - 692s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Schoffski, H. Dumez, P. Clement, A. Hoeben, H. Prenen, P. Wolter, S. Joniau, T. Roskams, and H. Van Poppel Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review Ann. Onc., August 1, 2006; 17(8): 1185 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Pasche A new strategy in the war on renal cell cancer: hitting multiple targets with limited collateral damage. JAMA, June 7, 2006; 295(21): 2537 - 2538. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wierecky, M. R. Muller, S. Wirths, E. Halder-Oehler, D. Dorfel, S. M. Schmidt, M. Hantschel, W. Brugger, S. Schroder, M. S. Horger, et al. Immunologic and Clinical Responses after Vaccinations with Peptide-Pulsed Dendritic Cells in Metastatic Renal Cancer Patients Cancer Res., June 1, 2006; 66(11): 5910 - 5918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kerr Concordia res parvae crescent Ann. Onc., January 1, 2006; 17(1): 3 - 4. [Full Text] [PDF]
|
|
|
|
|
|
J. Mestas, M. D. Burdick, K. Reckamp, A. Pantuck, R. A. Figlin, and R. M. Strieter The Role of CXCR2/CXCR2 Ligand Biological Axis in Renal Cell Carcinoma J. Immunol., October 15, 2005; 175(8): 5351 - 5357. [Abstract] [Full Text] [PDF]
|
|